Mizuho Securities analyst Mara Goldstein maintained a Buy rating on eFFECTOR Therapeutics (EFTR – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $0.74.
According to TipRanks, Goldstein is an analyst with an average return of -4.0% and a 34.07% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Arcus Biosciences, and Merck & Company.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for eFFECTOR Therapeutics with a $6.50 average price target.
See the top stocks recommended by analysts >>
EFTR market cap is currently $46.33M and has a P/E ratio of -1.29.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Locust Walk Acquisition Corp is a blank check company.
Read More on EFTR:
